CLINICAL_TRIALS ClinicalTrials.gov record update

An Open Label, Phase II Investigator Initiated Study of Venetoclax and Acalabrutinib in Previously Treated Relapsed/Refractory Patients With Mantle Cell Lymphoma (MCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03946878
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:24.796601+00:00
Published At: 2026-02-17T00:00:00+00:00
Record Updated At: 2026-02-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Blastoid Variant Mantle Cell Lymphoma", "CCND1 Protein Overexpression", "CD20 Positive", "CD5 Positive", "FCER2 Negative", "Pleomorphic Variant Mantle Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "t(11;14)(q13;q32)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-17"
protocolSection.identificationModule.nctId: "NCT03946878"
protocolSection.identificationModule.officialTitle: "An Open Label, Phase II Investigator Initiated Study of Venetoclax and Acalabrutinib in Previously Treated Relapsed/Refractory Patients With Mantle Cell Lymphoma (MCL)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.